Genetic polymorphisms modify the response of factor VII to oral contraceptive use: An example of gene-environment interaction

Vascular Pharmacology

Volumn 39, Issue 3, 2002, Pages 131-136

  Bloemenkamp, Kitty W M ^a,b   De Maat, Moniek P M ^b   Dersjant Roorda, Marianne C ^a   Helmerhorst, Frans M ^a   Kluft, Cornelis ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Factor VII; Genetic polymorphisms; Oral contraceptive

Indexed keywords

BLOOD CLOTTING FACTOR 7; CONTRACEPTIVE AGENT; DESOGESTREL; ETHINYLESTRADIOL; GESTODENE;

ADULT; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; CONTROLLED STUDY; DATA ANALYSIS; DNA POLYMORPHISM; FEMALE; FIBRINOGEN BLOOD LEVEL; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MULTIVARIATE ANALYSIS; NORMAL HUMAN; ORAL CONTRACEPTION; PRIORITY JOURNAL; RANDOMIZATION;

EID: 0345701535     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1537-1891(02)00300-2     Document Type: Conference Paper

References (40)

1. Bloemenkamp K.W.M., Rosendaal F.R., Helmerhorst F.M., Vandenbroucke J.P. Evidence that currently available pills are associated with cardiovascular disease: venous disease. Hannaford P.C., Webb A.M.C. Evidence-Guided Prescribing of the Pill. 1996;61-76 Parthenon Publishing, Carnforth.
2. Bloemenkamp K.W.M., Helmerhorst F.M., Dersjant-Roorda M.D., de Boer R., Meyer P., Spielmann D., Kluft C. A comparative clinical investigation of two low-dose oral contraceptives containing either 75 μg gestodene or 150 μg desogestrel combined with 20 μg ethinylestradiol: effect on hemostasis, lipid metabolism and carbohydrate metabolism. Gynecol. Endocrinol. 12:1998;21-30.
3. Consensus Development Meeting 1995: combined oral contraceptives and cardiovascular disease. Gynecol. Endocrinol. 10:1996;1-5.
4. de Maat M.P.M., Green F., de Knijff P., Jespersen J., Kluft C. Factor VII polymorphisms in populations with different risks of cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 7:1997;1918-1923.
5. Ferrer Antunes C., de Maat M.P.M., Palmeiro A., Pimentel J., Fernandes V. Association between polymorphisms in the fibrinogen alpha- and beta-genes on the post-trauma fibrinogen increase. Thromb. Res. 92:1998;207-212.
6. Fotherby K., Caldwell A.D.S. New progestogens in oral contraception. Contraception. 49:1994;1-32.
7. Gerstman B.B., Piper J.M., Tomita D.K., Ferguson W.J., Stadel B.V., Lundin F.E. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am. J. Epidemiol. 133:1991;32.
8. Gevers Leuven J.A., Kluft C., Dersjant-Roorda M.C., Harthoorn-Lastuizen E.J., Peters F.P.A.M.N., Bernsen M.J., Helmerhorst F.M. Changes in coagulation and fibrinolysis variables during use of two oral contraceptives containing the same dose of ethinyl estradiol and either gestodene or desogestrel. Adv. Contracept. 6:1990;69-73.
9. Green F., Kelleher C., Wilkes H., Temple A., Meade T., Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler. Thromb. 11:1991;540-546.
10. Green F., Hamsten A., Blombäck M., Humphries S. The role of β-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden. Thromb. Haemost. 70:1993;915-920.
11. Heinrich J., Funke H., Rust S., Schulte H., Schönfeld R., Köhler E., Assmann G. Impact of polymorphisms in the alpha- and beta-fibrinogen gene on plasma fibrinogen concentrations of coronary heart disease patients. Thromb. Res. 77:1995;209-215.
12. Housman D. Human DNA polymorphism. N. Engl. J. Med. 332:1995;318-320.
13. Humphries S.E., Cook M., Dubowitz M., Stirling Y., Meade T.W. Role of genetic variation at fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet. I:1987;1452-1455.
14. Humphries S.E., Lane A., Dawson S., Green F.R. The study of gene-environment interactions that influence thrombosis and fibrinolysis. Genetic variation at the loci for factor VII and plasminogen activator inhibitor-1. Arch. Pathol. Lab. Med. 116:1992;1322-1329.
15. Humphries S.E., Ye S., Talmud P., Bara L., Wilhelmsen L., Tiret L. European Atherosclerosis Research Study: genotype at the fibrinogen locus (G_455-A β-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe, evidence for gender-genotype-environment interaction. Arterioscler. Thromb. Vasc. Biol. 15:1995;96-104.
16. Humphries S.E., Panahloo A., Montgomery H.E., Green F., Yudkin J. Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Thromb. Haemost. 78:1997;457-461.
17. Iacoviello L., Di Castelnuovo A., De Knijff P., D'Orazio A., Amore C., Arboretti R., Kluft C., Benedetta Donati M. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N. Engl. J. Med. 338:1998;79-85.
18. Inman W.H.W., Vessey M.P., Westerholm B., Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives a report to the committee on safety of drugs. BMJ, Br. Med. J. 2:1970;203.
19. Iso H., Folsom A.R., Winkelmann J.C., Koike K., Harada S., Greenberg B., Sato S., Shimamoto T., Lida M., Komachi Y. Polymorphisms of beta fibrinogen gene and plasma fibrinogen concentration in Caucasian and Japanese population samples. Thromb. Haemost. 73:1995;106-111.
20. Jespersen J., Sidelmann J. A study of the conditions and accuracy of the thrombin time assay of plasma fibrinogen. Acta Haematol. 67:1982;2-7.
21. Jordan W.M. Pulmonary embolism. Lancet. 1:1961;1146-1147.
22. Kannel W.B., Wolf P.A., Castelli W.P., D'Agostino R.B. Fibrinogen and risk of cardiovascular disease; the Framingham Study. JAMA. 258:1987;1183-1186.
23. Kluft C., Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb. Haemost. 78:1997;315-326.
24. Koster T., Rosendaal F.R., Reitsma P.H., van der Velden P.A., Briët E., Vanderbroucke J.P. Factor VII and fibrinogen levels as risk factors for venous thrombosis: a case-control study of plasma levels and DNA polymorphisms, Leiden Thrombophilia Study (LETS). Thromb. Haemost. 71:1994;719-722.
25. Lane A., Cruickshank J., Mitchell J., Henderson A., Humphries S., Green F. Genetic and environmental determinants of factor VII coagulant activity in ethnic groups at differing risk of coronary heart disease. Atherosclerosis. 94:1992;43-50.
26. Meade T.W. Risks and mechanism of cardiovascular events in users of oral contraceptives. Am. J. Obstet. Gynecol. 158:1988;1646.
27. Meade T.W., Mellows S., Brozovic M., Miller G.J., Chakrabarti R.R., North W.R.S., Haines A.P., Stirling Y., Imeson J.D., Thompson S.G. Haemostatic function and ischaemic heart disease; principal results of the Northwick Park Heart Study. Lancet. 1986;533-537.
28. Mennen L.I., de Maat M.P.M., Schouten E.G., Kluft C., de Jong P.T.V.M., Hofman A., Grobbee D.E. Coagulation factor VII, serum-triglycerides and the R/Q353 polymorphism: differences between older men and women. Thromb. Haemost. 78:1997;984-986.
29. Mennen L.I., de Maat M.P.M., Schouten E.G., Kluft C., Witteman J.C.M., Hofman A., Grobbee D.E. Dietary effects on coagulation factor VII vary across genotypes of the R/Q353 polymorphism in elderly people. J. Nutr. 128:1998;870-874.
30. Middeldorp S., Meijers J.C.M., van den Ende A.E., van Enk A.E., Bouma B.N., Tans G., Rosing J., Prins M.H., Büller H.R. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb. Haemost. 84:2000;4-8.
31. Norris L.A., Bonnar J. The effect of oestrogen dose and progestogen type on the coagulation and fibrinolytic systems of a group of normal healthy women taking three different oral contraceptive combinations. Br. J. Obstet. Gynecol. 103:1996;261-267.
32. Oswaldsson U., Wilson S., Rosen S. A simple chromogenic assay for the determination of factor VII in microplates. Thromb. Haemost. 54:1985;26.
33. Palmeiro A., Carvalho-Sousa S., Ferrer-Antunes C. Polymorphism in the promotor region of the β-fibrinogen gene and fibrinogen plasma levels in an in-patient population. Thromb. Haemost. 72:1994;235-239.
34. Thomas A.E., Green F.R., Kelleher C.H., Wilkes H.C., Brennan P.J., Meade T.W., Humphries S.E. Variation in the promotor region of the β-fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb. Haemost. 65:1991;487-490.
35. Thomas A.E., Green F.R., Dawson S.J., Lane A., Henney A.M., Kelleher C.H., Wilkes H.C., Brennan P.J., Cruickshank J.K., Hamsten A., Wiman B., Meade T.W., Humphries S.E. Possibilities of DNA analysis for the detection of predisposition to thrombotic disease. Ann. N.Y. Acad. Sci. 667:1992;332-342.
36. Thomas A.E., Green F.R., Humphries S.E. Association of genetic variation at the beta-fibrinogen gene locus and plasma fibrinogen levels; interaction between allele frequency of the G/A-455 polymorphism, age and smoking. Clin. Genet. 50:1996;184-190.
37. Vandenbroucke J.P., Rosing J., Bloemenkamp K.W.M., Middeldorp S., Helmerhorst F.M., Bouma B.N., Rosendaal F.R. Oral contraceptives and the risk of venous thrombosis. N. Engl. J. Med. 344:2001;1527-1535.
38. Von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 17:1957;237-246.
39. Wilhelmsen L., Svardsudd K., Korsan-Bengtsen K., Larsson B., Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N. Engl. J. Med. 311:1984;501-505.
40. Cardiovascular disease and steroid hormone contraception. WHO Technical Report Series no. 877. 1998;. Geneva, Switzerland.